Avanafil Treatment Guidelines for Erectile Dysfunction

Special Considerations

• In patients with mild to moderate hepatic or renal impairment, use with caution at lower doses initially 1, 2

Efficacy Profile

• Avanafil has similar efficacy to other PDE5 inhibitors in the general ED population 1, 3, 4
• Men with diabetes and post-prostatectomy patients have more severe ED at baseline and may respond less robustly to avanafil and other PDE5 inhibitors 1, 3
• Combining testosterone therapy with avanafil may improve efficacy in men with both ED and testosterone deficiency 1, 2

Safety Profile and Adverse Effects

• Most common adverse events include headache, flushing, nasal congestion, nasopharyngitis, and back pain 1, 3
• Avanafil has the lowest rates of dyspepsia among PDE5 inhibitors 1, 5
• Like tadalafil, avanafil has lower rates of myalgia compared to other PDE5 inhibitors 1, 6

Optimizing Treatment Success

• Proper patient education is essential, as incorrect use accounts for many treatment failures 1, 2
• Patients should be instructed that sexual stimulation is necessary for the medication to work 1, 2
• Dose titration should be performed to balance efficacy and minimize adverse effects 1, 2
• For patients who fail initial therapy, ensure an adequate trial was conducted before considering alternative treatments 7

Cardiovascular Considerations

• Cardiovascular risk should be assessed for all men with ED before prescribing avanafil 7, 6
• Sexual activity is considered equivalent to walking 1 mile in 20 minutes or climbing 2 flights of stairs in 20 seconds 7
• Men unable to perform this level of exercise without symptoms should be referred to a cardiologist before treatment 7

Avanafil 200 mg: Efficacy and Safety Profile

Serious Side Effects

• Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported with PDE5 inhibitors, though causality remains uncertain, according to the Annals of Internal Medicine 8

Avanafil 200 mg Safety and Efficacy

Introduction to Avanafil

• The American Urological Association recommends that all three doses of avanafil (50, 100, 200 mg) showed similar efficacy to other PDE5 inhibitors in the general ED population 9

Efficacy Data

• Avanafil 200 mg demonstrated 64-71% successful intercourse attempts within 15 minutes of dosing compared to 27% with placebo, with efficacy maintained >6 hours post-dosing 9

Special Populations

• For patients with diabetes or post-prostatectomy, response may be less robust due to more severe baseline ED, according to The Journal of Urology 9